Ultragenyx Pharmaceutical Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Emil D. Kakkis
- Full Time Employees
- 1,371
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 60 Leveroni Court Novato CA United States of America 94949
- IPO Date
- Jan 31, 2014
- CIK
- 0001515673
- Website
- ultragenyx.com
- Similar Companies
- Business
- Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare and ultrarare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company offers approved products including Crysvita (burosumab) for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii for mucopolysaccharidosis VII; and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders; alongside a robust pipeline targeting conditions such as Angelman syndrome with GTX-102. Ultragenyx operates globally, with commercial presence in North America, Europe, and select international markets, serving patients through specialized support programs like UltraCare. In recent developments, Ultragenyx sold a portion of future North American royalties on Crysvita to OMERS Life Sciences for $400 million in November 2025; reported third quarter 2025 financial results with total revenue guidance of $640 million to $670 million; dosed the first patient in the Aurora study for GTX-102 in Angelman syndrome in October 2025; and appointed Eric Olson as Chief Business Officer in September 2025.
Company News
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)
Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE)
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
JAGUAR URANIUM REPORTS RARE EARTH OXIDES ASSOCIATED WITH URANIUM-PHOSPHATE-VANADIUM MINERALIZATION AT THE BERLIN ASSET IN COLOMBIA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
ULTRA-RARE MCA CENTENAIRE, MONACO'S FIRST SUPERCAR, OFFERED AT BROAD ARROW'S 2026 ZOUTE CONCOURS AUCTION
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?